

Egalet Corp  
Form SC 13G/A  
February 10, 2016

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**SCHEDULE 13G**

**(Rule 13d-102)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1 (b), (c) AND  
(d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2**

**(Amendment No. 1)**

**Egalet Corporation**

**(Name of Issuer)**

**Common Stock, \$0.001 par value**

**(Title of Class of Securities)**

**28226B104**

**(CUSIP Number)**

**December 31, 2015**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ **Rule 13d-1(d)**

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( " Act ") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**Omega Fund IV, L.P.**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

**Cayman Islands**

5 SOLE VOTING POWER

NUMBER OF

SHARES 0  
6 SHARED VOTING POWER

BENEFICIALLY

OWNED BY  
EACH 314,574  
7 SOLE DISPOSITIVE POWER

REPORTING

PERSON 0  
8 SHARED DISPOSITIVE POWER

WITH

**314,574**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**314,574**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**1.26%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**PN**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( "Omega Fund" ), Omega Fund IV GP, L.P. ( "Omega GP" ), Omega Fund IV G.P. Manager, Ltd. ( "Omega Ltd" ), Richard Lim ( "Lim" ), Otello Stampacchia ( "Stampacchia" ), Anne-Mari Paster ( "Paster" ), Danish Biotech SPV I P/S ( "Danish Biotech" ), Danish Biotech SPV I, GP Ltd. ( "Danish Biotech Ltd" ), David Bolton ( "Bolton" ), and Martin Mullins ( "Mullins" ) (together, the "Reporting Persons" ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer's most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.

CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**Omega Fund IV GP, L.P.**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

**Cayman Islands**

5 ☐ SOLE VOTING POWER

NUMBER OF

SHARES **0**

6 ☐ SHARED VOTING POWER

BENEFICIALLY

OWNED BY **314,574**

EACH ☒ 7 SOLE DISPOSITIVE POWER

REPORTING

PERSON **0**

8 ☐ SHARED DISPOSITIVE POWER

WITH

**314,574**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**314,574**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**1.26%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**PN**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( Omega Fund ), Omega Fund IV GP, L.P. ( Omega GP ), Omega Fund IV G.P. Manager, Ltd. ( Omega Ltd ), Richard Lim ( Lim ), Otello Stampacchia ( Stampacchia ), Anne-Mari Paster ( Paster ), Danish Biotech SPV I P/S ( Danish Biotech ), Danish Biotech SPV I, GP Ltd. ( Danish Biotech Ltd ), David Bolton ( Bolton ), and Martin Mullins ( Mullins ) (together, the Reporting Persons ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer s most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.

CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**Omega Fund IV G.P. Manager, Ltd.**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

**Cayman Islands**

5 ☐ SOLE VOTING POWER

NUMBER OF

SHARES **0**

6 ☐ SHARED VOTING POWER

BENEFICIALLY

OWNED BY **314,574**

EACH ☐ 7 ☐ SOLE DISPOSITIVE POWER

REPORTING

PERSON **0**

8 ☐ SHARED DISPOSITIVE POWER

WITH

**314,574**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**314,574**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**1.26%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**OO**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( "Omega Fund" ), Omega Fund IV GP, L.P. ( "Omega GP" ), Omega Fund IV G.P. Manager, Ltd. ( "Omega Ltd" ), Richard Lim ( "Lim" ), Otello Stampacchia ( "Stampacchia" ), Anne-Mari Paster ( "Paster" ), Danish Biotech SPV I P/S ( "Danish Biotech" ), Danish Biotech SPV I, GP Ltd. ( "Danish Biotech Ltd" ), David Bolton ( "Bolton" ), and Martin Mullins ( "Mullins" ) (together, the "Reporting Persons" ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer's most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.



CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**Richard Lim**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

5 ☐ SOLE VOTING POWER

NUMBER OF

SHARES **0**

6 ☐ SHARED VOTING POWER

BENEFICIALLY

OWNED BY **314,574**

EACH

7 ☐ SOLE DISPOSITIVE POWER

REPORTING

PERSON **0**

8 ☐ SHARED DISPOSITIVE POWER

WITH

**314,574**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**314,574**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**1.26%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**IN**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( Omega Fund ), Omega Fund IV GP, L.P. ( Omega GP ), Omega Fund IV G.P. Manager, Ltd. ( Omega Ltd ), Richard Lim ( Lim ), Otello Stampacchia ( Stampacchia ), Anne-Mari Paster ( Paster ), Danish Biotech SPV I P/S ( Danish Biotech ), Danish Biotech SPV I, GP Ltd. ( Danish Biotech Ltd ), David Bolton ( Bolton ), and Martin Mullins ( Mullins ) (together, the Reporting Persons ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer s most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.

CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**Otello Stampacchia**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

**Italy**

5 SOLE VOTING POWER

NUMBER OF

SHARES **0**

6 SHARED VOTING POWER

BENEFICIALLY

OWNED BY **314,574**

EACH 7 SOLE DISPOSITIVE POWER

REPORTING

PERSON **0**

8 SHARED DISPOSITIVE POWER

WITH

**314,574**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**314,574**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**1.26%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**IN**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( "Omega Fund" ), Omega Fund IV GP, L.P. ( "Omega GP" ), Omega Fund IV G.P. Manager, Ltd. ( "Omega Ltd" ), Richard Lim ( "Lim" ), Otello Stampacchia ( "Stampacchia" ), Anne-Mari Paster ( "Paster" ), Danish Biotech SPV I P/S ( "Danish Biotech" ), Danish Biotech SPV I, GP Ltd. ( "Danish Biotech Ltd" ), David Bolton ( "Bolton" ), and Martin Mullins ( "Mullins" ) (together, the "Reporting Persons" ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer's most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.

CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**Anne-Mari Paster**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

**United States of America**

5 ☐ SOLE VOTING POWER

NUMBER OF

SHARES **0**  
6 ☐ SHARED VOTING POWER

BENEFICIALLY

OWNED BY **314,574**  
EACH 7 ☐ SOLE DISPOSITIVE POWER

REPORTING

PERSON **0**  
8 ☐ SHARED DISPOSITIVE POWER

WITH

**314,574**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**314,574**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**1.26%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**IN**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( "Omega Fund" ), Omega Fund IV GP, L.P. ( "Omega GP" ), Omega Fund IV G.P. Manager, Ltd. ( "Omega Ltd" ), Richard Lim ( "Lim" ), Otello Stampacchia ( "Stampacchia" ), Anne-Mari Paster ( "Paster" ), Danish Biotech SPV I P/S ( "Danish Biotech" ), Danish Biotech SPV I, GP Ltd. ( "Danish Biotech Ltd" ), David Bolton ( "Bolton" ), and Martin Mullins ( "Mullins" ) (together, the "Reporting Persons" ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer's most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.

CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**Danish Biotech SPV I P/S**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

**Denmark**

5 SOLE VOTING POWER

NUMBER OF

SHARES **0**  
6 SHARED VOTING POWER

BENEFICIALLY

OWNED BY **2,500,354**  
EACH 7 SOLE DISPOSITIVE POWER

REPORTING

PERSON **0**  
8 SHARED DISPOSITIVE POWER

WITH

**2,500,354**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**2,500,354**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**9.98%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**PN**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( Omega Fund ), Omega Fund IV GP, L.P. ( Omega GP ), Omega Fund IV G.P. Manager, Ltd. ( Omega Ltd ), Richard Lim ( Lim ), Otello Stampacchia ( Stampacchia ), Anne-Mari Paster ( Paster ), Danish Biotech SPV I P/S ( Danish Biotech ), Danish Biotech SPV I, GP Ltd. ( Danish Biotech Ltd ), David Bolton ( Bolton ), and Martin Mullins ( Mullins ) (together, the Reporting Persons ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer s most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.



CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**Danish Biotech SPV I, GP Ltd.**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

**Guernsey**

5 SOLE VOTING POWER

NUMBER OF

SHARES **0**  
6 SHARED VOTING POWER

BENEFICIALLY

OWNED BY **2,500,354**  
EACH 7 SOLE DISPOSITIVE POWER

REPORTING

PERSON **0**  
8 SHARED DISPOSITIVE POWER

WITH

**2,500,354**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**2,500,354**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**9.98%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**OO**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( Omega Fund ), Omega Fund IV GP, L.P. ( Omega GP ), Omega Fund IV G.P. Manager, Ltd. ( Omega Ltd ), Richard Lim ( Lim ), Otello Stampacchia ( Stampacchia ), Anne-Mari Paster ( Paster ), Danish Biotech SPV I P/S ( Danish Biotech ), Danish Biotech SPV I, GP Ltd. ( Danish Biotech Ltd ), David Bolton ( Bolton ), and Martin Mullins ( Mullins ) (together, the Reporting Persons ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer s most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.

CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**David Bolton**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

**United Kingdom**

5 SOLE VOTING POWER

NUMBER OF

SHARES **0**

6 SHARED VOTING POWER

BENEFICIALLY

OWNED BY **2,500,354**

EACH 7 SOLE DISPOSITIVE POWER

REPORTING

PERSON **0**

8 SHARED DISPOSITIVE POWER

WITH

**2,500,354**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**2,500,354**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**9.98%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**IN**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( "Omega Fund" ), Omega Fund IV GP, L.P. ( "Omega GP" ), Omega Fund IV G.P. Manager, Ltd. ( "Omega Ltd" ), Richard Lim ( "Lim" ), Otello Stampacchia ( "Stampacchia" ), Anne-Mari Paster ( "Paster" ), Danish Biotech SPV I P/S ( "Danish Biotech" ), Danish Biotech SPV I, GP Ltd. ( "Danish Biotech Ltd" ), David Bolton ( "Bolton" ), and Martin Mullins ( "Mullins" ) (together, the "Reporting Persons" ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer's most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.

CUSIP NO. **28226B104**

13G

1 NAMES OF REPORTING PERSONS

**Martin Mullins**

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒ (1)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

**United Kingdom**

5 SOLE VOTING POWER

NUMBER OF

SHARES **0**  
6 SHARED VOTING POWER

BENEFICIALLY

OWNED BY **2,500,354**  
EACH 7 SOLE DISPOSITIVE POWER

REPORTING

PERSON **0**  
8 SHARED DISPOSITIVE POWER

WITH

**2,500,354**

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**2,500,354**

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

..

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

**9.98%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

**IN**

- (1) This Schedule 13G is filed by Omega Fund IV, L.P. ( Omega Fund ), Omega Fund IV GP, L.P. ( Omega GP ), Omega Fund IV G.P. Manager, Ltd. ( Omega Ltd ), Richard Lim ( Lim ), Otello Stampacchia ( Stampacchia ), Anne-Mari Paster ( Paster ), Danish Biotech SPV I P/S ( Danish Biotech ), Danish Biotech SPV I, GP Ltd. ( Danish Biotech Ltd ), David Bolton ( Bolton ), and Martin Mullins ( Mullins ) (together, the Reporting Persons ). Omega L serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech. The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.
- (2) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer s most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.

CUSIP NO. **28226B104**

13G

Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value \$0.001 per share ( Common Stock ), of Egalet Corporation (the Issuer ).

**Item 1(a) Name of Issuer:**

**Item 1(b) Address of issuer's principal executive offices:**

Egalet Corporation

460 East Swedesford Road, Suite 1050

Wayne, PA 19078

**Items 2(a) Name of Reporting Persons filing:**

Omega Fund IV, L.P. ( Omega Fund )

Omega Fund IV GP, L.P. ( Omega GP )

Omega Fund IV G.P. Manager, Ltd. ( Omega Ltd. )

Richard Lim ( Lim )

Otello Stampacchia ( Stampacchia )

Anne-Mari Paster ( Paster )

Danish Biotech SPV I P/S ( Danish Biotech )

Danish Biotech SPV I, GP Ltd. ( Danish Biotech Ltd )

David Bolton ( Bolton )

Martin Mullins ( Mullins )

**Item 2(b) Address or principal business office or, if none, residence:**

The address of the principal business office of Omega Fund, Omega GP, Omega Ltd, Lim, Stampacchia, Paster, Bolton, Mullins, and Danish Biotech Ltd is c/o IPES (Guernsey) Limited, 1 Royal Plaza, Royal Avenue, St. Peter Port, Guernsey GY 1 2HL, Channel Islands, UK. The address of the principal business office of Danish Biotech is c/o Gorrissen Federspiel Kierkegaard, H.C. Andersens Boulevard 12, 1553 Copenhagen, Denmark.

**Item 2(c)      Citizenship:**

<b>Name</b>	<b>Citizenship or Place of Organization</b>
Omega Fund	Cayman Islands
Omega GP	Cayman Islands
Omega Ltd.	Cayman Islands
Lim	United States of America
Stampacchia	Italy
Paster	United States of America
Danish Biotech	Denmark
Danish Biotech Ltd	Guernsey
Bolton	United Kingdom
Mullins	United Kingdom

**Item 2(d)      Title of class of securities:**

Common Stock, \$0.001 par value per share

**Item 2(e)      CUSIP No.:**

28226B104

**Item 3            If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:**

Not applicable.



CUSIP NO. 28226B104

13G

**Item 4 Ownership**

The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2015:

Reporting Persons	Shares of Common					Beneficial Ownership	Percentage of Class (1)
	Stock Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power		
Omega Fund(2)(4)	314,574	0	314,574	0	314,574	314,574	1.26%
Omega GP(2)(4)	314,574	0	314,574	0	314,574	314,574	1.26%
Omega Ltd(2)(4)	314,574	0	314,574	0	314,574	314,574	1.26%
Lim (2)(4)	314,574	0	314,574	0	314,574	314,574	1.26%
Stampacchia(2)(4)	314,574	0	314,574	0	314,574	314,574	1.26%
Paster(2)(4)	314,574	0	314,574	0	314,574	314,574	1.26%
Danish Biotech(3)(4)	2,500,354	0	2,500,354	0	2,500,354	2,500,354	9.98%
Danish Biotech Ltd(3)(4)	2,500,354	0	2,500,354	0	2,500,354	2,500,354	9.98%
Bolton(3)(4)	2,500,354	0	2,500,354	0	2,500,354	2,500,354	9.98%
Mullins(3)(4)	2,500,354	0	2,500,354	0	2,500,354	2,500,354	9.98%

- (1) This percentage is calculated based upon 25,059,474 shares of the Common Stock outstanding as of November 6, 2015 as set forth in the Issuer's most recent Form 10-Q for the period ending September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015.
- (2) Omega Fund owns 314,574 shares. Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund, and each of Omega GP and Omega Ltd may be deemed to own beneficially the shares held by Omega Fund. Lim, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund.
- (3) Danish Biotech owns 2,500,354 shares. Danish Biotech Ltd is the general partner of Danish Biotech and may be deemed to beneficially own the shares held by Danish Biotech. Bolton and Mullins are the directors of Danish Biotech Ltd and may be deemed to beneficially own the shares held by Danish Biotech.
- (4) The Reporting Persons may be deemed a group for purposes of Section 13 of the Exchange Act and expressly disclaim status as a group for purposes of this Schedule 13G.

**Item 5 Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ( ).

**Item 6 Ownership of More than Five Percent on Behalf of Another Person**

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: "

**Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person**

Not applicable.

CUSIP NO. **28226B104**

13G

**Item 8 Identification and Classification of Members of the Group**

Not applicable.

**Item 9 Notice of Dissolution of Group**

Not applicable.

**Item 10 Certifications**

Not applicable.

---

CUSIP NO. **28226B104**

13G

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 10, 2016

OMEGA FUND IV, L.P.

BY: Omega Fund IV GP, L. P

ITS: GENERAL PARTNER

BY: Omega Fund IV G.P. Manager, Ltd.

ITS: GENERAL PARTNER

By: /s/ Richard Lim  
Director

OMEGA FUND IV GP, L.P

BY: Omega Fund IV G.P. Manager, Ltd.

ITS: GENERAL PARTNER

By: /s/ Richard Lim  
Director

OMEGA FUND IV G.P. MANAGER, LTD.

By: /s/ Richard Lim  
Director

/s/ Richard Lim  
Richard Lim

/s/ Otello Stampacchia  
Otello Stampacchia

/s/ Anne-Mari Paster  
Anne-Mari Paster

DANISH BIOTECH SPV I P/S

By: /s/ David Bolton  
Director

By: /s/ Martin Mullins  
Director

DANISH BIOTECH SPV I, GP Ltd.

By: /s/ Martin Mullins  
Director

CUSIP NO. **28226B104**

13G

/s/ David Bolton  
David Bolton

/s/ Martin Mullins  
Martin Mullins  
**Exhibit(s):**

Exhibit 99.1:     Joint Filing Statement